Key result
Arsenic trioxide-induced cardiotoxicity in acute promyelocytic leukemia involves molecular pathways that increase reactive oxygen species and alter microRNA expression.
Why the study?
Arsenic trioxide improves outcomes in acute promyelocytic leukemia but causes serious cardiotoxicity that can lead to death, warranting an evaluation of reports and reduction strategies.
Targeting microRNAs and molecular pathways involved in calcium homeostasis and reactive oxygen species production may offer a novel strategy to prevent arsenic trioxide-induced cardiotoxicity in APL patients.
Answers are grounded in this paper and cite their sources.
Suggests targets to mitigate arsenic trioxide cardiotoxicity in APL; leaves open clinical validation of microRNA-based interventions.
OBJECTIVE: Arsenic trioxide (ATO) is a drug commonly used for the treatment of acute promyelocytic leukemia (APL). Although ATO has been shown to cause significant improvement in patients, it is associated with serious side effects, which sometimes lead to the patient's death. In this review paper, we examine the reports of ATO-induced cardiotoxicity in APL patients and evaluate the strategies to reduce the incidence of such toxicity. METHODS: The key search terms were "arsenic trioxide," "acute promyelocytic leukemia," "cardiotoxicity," "molecular pathway," and "biomarker." RESULTS: Studies have indicated the involvement of several molecular pathways in ATO-induced cardiotoxicity. These pathways increase the production of reactive oxygen species by interfering with intracellular calcium homeostasis as well as impairing the transfer of calcium into endoplasmic reticulum and mitochondria. On the other hand, increasing or decreasing expressions of some microRNAs (miRs) have been shown to play a role in cardiotoxicity. CONCLUSION: Finally, it can be stated that given the essential role of molecular pathways in cardiotoxicity and considering the fact these pathways impair the regulation of miRs expression, identification of molecular pathways involved in ATO-induced cardiotoxicity aimed at targeting miRs could be a new therapeutic strategy to prevent cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Haybar et al. (2019) conducted a review in Acute promyelocytic leukemia (APL). Arsenic trioxide (ATO) was evaluated on ATO-induced cardiotoxicity. Arsenic trioxide-induced cardiotoxicity in acute promyelocytic leukemia involves molecular pathways that increase reactive oxygen species and alter microRNA expression.
Synapse has enriched 10 related papers. Consider them for comparative context: